||Last Updated: Nov 17th, 2006 - 22:35:04
Phase Ib Trial Is Evaluating Bavituximab Administered With Common Chemotherapy Regimens
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapeutics for the treatment of cancer and hepatitis C virus (HCV) infection, today announced initiation of patient treatment in its Phase lb clinical trial to evaluate its lead anti-phospholipid immunotherapy agent bavituximab given in combination with common cancer chemotherapy agents. The trial is expected to enroll up to 12 patients at three clinical sites in India.
Nov 17, 2006, 22:32
Two-component lantibiotic with therapeutic potential discovered
The discovery and preparation of a naturally occurring antibiotic could open the door to new therapeutic drugs for treating nasty infections. The rapid spread of drug-resistant bacterial strains poses a persistent threat to human health, and requires new sources of antibiotics to treat infections. Researchers at the University of Illinois at Urbana-Champaign are tackling this problem by discovering and preparing natural antibiotics called lantibiotics.
Oct 31, 2006, 16:13
Prescription pain medication abuse on rise
Researchers at Rush University Medical Center found prescription pain medication (PPM) abuse is a rapidly growing problem with surprising and often unpredictable distribution patterns. The research was presented at the Annual Meeting of the American Society for Anesthesiologists in Chicago, October 13, 2006.
Oct 17, 2006, 02:16
Antibiotic inhibits cancer gene activity
A little-known antibiotic shows early promise as an anti-cancer agent, inhibiting a gene found at higher-than-normal levels in most human tumors, according to researchers at the University of Illinois at Chicago College of Medicine.
Oct 2, 2006, 01:39
NRTIs limits the atherogenic side effect of the protease inhibitors
Physiologists may have found a way to decrease the risk of hardening of the arteries that accompanies the long-term use of protease inhibitors, a class of drugs that has emerged as the most effective treatment against HIV and AIDS.
Sep 5, 2006, 18:20
Cyclin-dependent kinase inhibitors: The latest anti-inflammatory
People who suffer from inflammatory conditions such as chronic diseases of the lung, joints and other organs could benefit from a new discovery by scientists at the University of Edinburgh. A new study in Nature Medicine journal shows that certain drugs, already being tested as cancer treatments, can dramatically reduce tissue inflammation.
Sep 4, 2006, 16:41
FDA requested to promptly approve 17-P to prevent premature birth
The March of Dimes today urged Food and Drug Administration officials to promptly approve a commercial progesterone therapy that appears to prevent some premature births.
Aug 29, 2006, 21:03
Rapamycin shown to inhibit angiogenesis
Scientists have long known that the blood vessels of tumors differ markedly from normal blood vessels. Now, a research team led by scientists at Beth Israel Deaconess Medical Center (BIDMC) has identified a signaling pathway which, when activated, transforms otherwise healthy blood vessels into the leaky, misshapen vasculature that characterizes cancerous tumors.
Aug 15, 2006, 02:48
Tigecycline, world’s first glycylcycline expanded broad-spectrum antibiotic, launched in UK
Tygacil (tigecycline), a new, expanded broad-spectrum IV antibiotic for the treatment of a wide range of infections including those caused by antibiotic resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), 1 will be available in the UK from 20 June 2006. Availability of this new antibiotic comes at a time when the need for effective new treatments is greater than ever and clinicians are running out of options.
Jul 22, 2006, 19:18
Ibuprofen - worsening cognitive function
Researchers at the University of Pennsylvania School of Medicine found that chronic ibuprofen therapy given after brain injury worsens cognitive abilities. These findings – in a preliminary, animal-model study – have important implications for traumatic brain injury (TBI) patients who are often prescribed such nonsteroidal anti-inflammatory drugs (NSAIDS) as ibuprofen for chronic pain.
Jul 22, 2006, 05:22
Anti-angiogenics: a novel class of drugs against solid tumors
Researchers at the University of Minnesota have developed novel anti-cancer drugs to treat solid tumors. These "small molecules" belong to a class of pharmaceutical agents called anti-angiogenics. The new compounds are a refined form of drugs that effectively reduce blood flow to the tumor, thereby inhibiting tumor growth.
Jul 6, 2006, 03:04
FDA Warns of Liver Failure With Telithromycin
The Food and Drug Administration (FDA) today completed its safety assessment of Telithromycin and is advising health practitioners and patients to be aware of rare but potentially serious health risks. Ketek (telithromycin) is the first FDA-approved antibiotic of the ketolide class. It is indicated for the treatment of acute exacerbation of chronic bronchitis; acute bacterial sinusitis; and community acquired pneumonia of mild to moderate severity, including pneumonia caused by resistant strep infections. The drug has been associated with rare cases of serious liver injury and liver failure with four reported deaths and one liver transplant after the administration of the drug. The manufacturer is revising the drug labeling to address this safety concern.
Jun 30, 2006, 13:13
Phosphodiesterase-5 inhibitors (PDE-5i) produce beneficial results for wide range of conditions
Since the Food and Drug Administration gave sildenafil its approval in 1998, "erectile dysfunction" has become a household term – probably to the chagrin of many parents fielding questions from their kids watching TV. But with sildenafil and the subsequent introduction and marketing of vardenafil and tadalafil, many men have found answers to a once-unmentionable condition.
Jun 19, 2006, 01:56
What is the optimal duration of antibiotic therapy?
Taking antibiotics for three days is just as effective for community acquired pneumonia as continuing treatment for the recommended 7-10 days, finds a study in this week’s BMJ. Shorter treatment can also help contain growing resistance rates. The study raises questions about the optimal duration of antibiotic therapy for common infections. Community acquired pneumonia is one of the most important indications for antibiotic prescriptions in hospitals. But a lack of evidence to support short course therapy means it has become accepted practice to continue treatment for days after symptoms have improved.
Jun 10, 2006, 17:48
CCB and ACE inhibitors reduce diabetes risk in Hispanic patients
The combination of drugs traditionally used to control blood pressure might not be ideal for Hispanic patients, University of Florida researchers warn.
Jun 8, 2006, 16:39
ACE inhibitors implicated in birth defects
The Food and Drug Administration is examining study data from Vanderbilt University Medical Center researchers, published this week in the New England Journal of Medicine, to determine if new warnings should be placed on common blood pressure medications indicating an increased risk of birth defects for babies whose mothers take these medications during the first trimester of pregnancy.
Jun 8, 2006, 16:37
Ramelteon shows less potential to foster abuse and dependence
As part of the effort to develop effective behavioral and medical sleep therapies, scientists consider the potential for dependence and abuse associated with prescription sleep drugs. This line of research has produced findings showing that a recently approved prescription sleep drug may spare users the potential for dependence and abuse found with other sleep aids. Laboratory studies of the effects of ramelteon suggest that the drug's targeting of the brain's melatonin receptors rather than its benzodiazepine receptors make its subjective side effects different from those of old and new sedative hypnotics.
Jun 5, 2006, 16:19
Should children with suspected meningitis be given antibiotics before transfer to hospital?
Several European countries advise doctors in primary care to do this, but the evidence is conflicting, with some studies suggesting benefit and others suggesting harm. Two papers in this week’s BMJ add to this uncertainty.
Jun 2, 2006, 23:05
COX 2 inhibitors associated with increased risk of vascular events
High doses of some traditional non-steroidal anti-inflammatory drugs (NSAIDS) are associated with similar cardiovascular risks as the new generation of anti-inflammatory drugs known as COX 2 inhibitors (like Vioxx ®), finds a study in this week's BMJ.
Jun 2, 2006, 22:55
Complete Inhibition of Viral Replication in H5N1 In Vivo Model by Bavituximab
Peregrine Pharmaceuticals, a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for the treatment of hepatitis C virus (HCV) infection and cancer, today announced that its lead anti-viral compound bavituximab (formerly Tarvacin) completely inhibited replication of a laboratory strain of the H5N1 virus, commonly known as avian flu, in fertilized chicken eggs, an in vivo model for influenza anti- viral activity. These preliminary findings will be reported today at the 106th general meeting of The American Society for Microbiology (ASM) in Orlando, Florida by Dr. Philip Thorpe, a member of the Peregrine Scientific Resource Board and professor of pharmacology at the University of Texas Southwestern Medical Center at Dallas. Bavituximab, a monoclonal antibody with unique anti-viral and anti-cancer properties, has already demonstrated good tolerability in a Phase l trial in patients with HCV infection.
May 25, 2006, 13:09
FDA Approves Rasagiline for Parkinson's Disease
The Food and Drug Administration today approved Azilect (rasagiline), a new molecular entity, for the treatment of Parkinson's disease. The drug is a monoamine oxidase type--B (MAO-B) inhibitor that blocks the breakdown of dopamine, a chemical that sends information to the parts of the brain that control movement and coordination.
May 20, 2006, 03:04
FDA Gives Tentative Approval to Abacavir
The Food and Drug Administration (FDA) today announced the tentative approval of generic abacavir (a-BAK-a-veer) sulfate tablets manufactured by Aurobindo Pharma LTD. of Hyderabad, India. Abacavir sulfate tablets are the first generic version of the already approved Ziagen Tablets, an anti-HIV medication manufactured by GlaxoSmithKline. This product will now be available for consideration for purchase under the President's Emergency Plan for AIDS Relief.
May 20, 2006, 03:01
FDA Approves Remicade for Crohnâ€™s Disease in Children
The Food and Drug Administration today approved Remicade (infliximab) to treat children with active Crohn's disease, a chronic, inflammatory condition of the bowel that can be severely debilitating. Remicade is a genetically engineered monoclonal antibody, which reduces inflammation (swelling/redness) by blocking the action of tumor necrosis factor-alpha (TNF-Î±), that was initially approved in 1998 to treat Crohn's disease in adults.
May 20, 2006, 02:57
FDA Approves Varenicline for Smoking Cessation
The U.S. Food and Drug Administration (FDA) announced today the approval of Chantix (varenicline tartrate) tablets, to help cigarette smokers stop smoking. The active ingredient in Chantix, varenicline tartrate, is a new molecular entity that received a priority FDA review because of its significant potential benefit to public health.
May 20, 2006, 02:53
Production Practices Effect Antimicrobial Resistance in Poultry
The use of conventional versus organic production practices can significantly affect the prevalence of antibiotic resistant to bacteria in poultry say researchers from Maryland and Ohio. Their findings appear in the May 2006 issue of the journal Applied and Environmental Microbiology.
May 15, 2006, 17:27
Desensitization protocol overcomes allergy to clopidogrel
A careful desensitization protocol can help patients overcome allergic reactions to anti-clotting medication critical to preventing new blockages inside coronary stents, according to a study being presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 29th Annual Scientific Sessions in Chicago, May 10–13.
May 12, 2006, 14:18
Varenicline could increase number who quit smoking
Smokers who try to quit using existing medications, such as nicotine patches or Zyban, are about twice as likely to succeed as those who don't use medication or are prescribed placebos during clinical trials. But despite the relative effectiveness of medications currently on the market, more than 80 per cent of quitters will be smoking again within a year, according to a review in the latest IJCP, the UK-based International Journal of Clinical Practice.
May 7, 2006, 19:53
NDA submitted for Gestiva for the prevention of preterm delivery
Adeza (NASDAQ:ADZA) today announced the submission of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for Gestiva(TM), the company's drug candidate to prevent preterm birth in women with a history of preterm delivery.
May 6, 2006, 00:47
Aspirin Protects Against Aminoglycoside Induced Hearing Loss
Around the world, inexpensive antibiotics known as aminoglycosides have been used for the past 60 years in the battles against acute infections and tuberculosis as antibacterial prophylaxis in cystic fibrosis patients and in other conditions. But for all of the good they do, the drugs also have been widely linked to irreversible hearing loss. Now, researchers at the University of Michigan's Kresge Hearing Research Institute and their Chinese colleagues, working under the leadership of Jochen Schacht, Ph.D., and Su-Hua Sha, M.D., have found that the hearing loss can be prevented in many people with the use of another inexpensive, widely available medication: aspirin. The results appear in the April 27 issue of the New England Journal of Medicine.
Apr 27, 2006, 13:45
Higher Initial Doses of FOSRENOL Result in More Rapid Control of Mean Serum Phosphorus
According to data presented today at the National Kidney Foundation's (NKF) 2006 clinical meeting in Chicago, IL, a conversion to the non-calcium phosphate binder FOSRENOL (lanthanum carbonate) from other phosphate binder therapies provides continued mean serum phosphorus control for end-stage renal disease (ESRD) patients with hyperphosphatemia, while significantly reducing their daily tablet burden and the total daily dose of phosphate binder medication.
Apr 23, 2006, 19:11